Basit öğe kaydını göster

dc.contributor.authorKullberg, B. J.
dc.contributor.authorVerweij, P. E.
dc.contributor.authorAkova, M.
dc.contributor.authorArendrup, M. C.
dc.contributor.authorBille, J.
dc.contributor.authorCalandra, T.
dc.contributor.authorCuenca-Estrella, M.
dc.contributor.authorHerbrecht, R.
dc.contributor.authorJacobs, F.
dc.contributor.authorKalin, M.
dc.contributor.authorKibbler, C. C.
dc.contributor.authorLortholary, O.
dc.contributor.authorMartino, P.
dc.contributor.authorMeis, J. F.
dc.contributor.authorMunoz, P.
dc.contributor.authorOdds, F. C.
dc.contributor.authorDe Pauw, B. E.
dc.contributor.authorRex, J. H.
dc.contributor.authorRoilides, E.
dc.contributor.authorRogers, T. R.
dc.contributor.authorRuhnke, M.
dc.contributor.authorUllmann, A. J.
dc.contributor.authorUzun, O.
dc.contributor.authorVandewoude, K.
dc.contributor.authorVincent, J. -L.
dc.contributor.authorDonnelly, J. P.
dc.date.accessioned2019-12-10T11:12:56Z
dc.date.available2019-12-10T11:12:56Z
dc.date.issued2011
dc.identifier.issn1198-743X
dc.identifier.urihttps://doi.org/10.1111/j.1469-0691.2011.03615.x
dc.identifier.urihttp://hdl.handle.net/11655/15049
dc.description.abstractThis report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and developments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole antifungals, and the presence of potentially antifungal drug-resistant Candida species.
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.isversionof10.1111/j.1469-0691.2011.03615.x
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInfectious Diseases
dc.subjectMicrobiology
dc.titleEuropean Expert Opinion On The Management Of Invasive Candidiasis In Adults
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalClinical Microbiology And Infection
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume17
dc.identifier.startpage1
dc.identifier.endpage12
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster